INTRODUCTION
The use of neuraminidase inhibitors is usually It is well-recognized that the use of neuraminidase inhibitor can effectively shorten the symptomatic period of influenza. 4−9 In addition, evidence suggests that the early use of certain neuraminidase inhibitors may decrease mortality and hospitalization due to influenza-in particular pandemic 2009 influenza A H1N1. 10, 11 However, the application of neuraminidase inhibitors to every case of influenza may pose serious threats to patient safety and public health, including adverse effects, the emergence of drug resistance, and rising medication expenses. Overuse of neuraminidase inhibitors can also lead to logistical problems, particularly during a pandemic.
Gingyo-gedoku-san（GGGS）is an herbal medication containing extracts from plants and animal products. GGGS is approved for over the counter （OTC）use to treat upper respiratory infections in Japan. However, its efficacy against influenza has not been evaluated at the clinical investigative level.
Therefore, we conducted a pilot study aimed at evaluating the efficacy of GGGS against influenza and influenza-like illness（ILI）in comparison to a globally recognized neuraminidase inhibitor, oseltamivir.
MATERIALS AND METHODS

Study design
This is an open-label, unblinded, multi-center, prospective comparative study, comparing GGGS with oseltamivir in the management of influenza and ILI. Influenza has gained notoriety in Japan, largely due to the 2009 pandemic that struck the country.
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We conducted an open-label, multi-center, prospective trial, comparing GGGS with oseltamivir in patients with influenza and influenza-like illness（ILI）as a pilot study.
Methods: Subjects were healthy persons aged between 16 and 40, and were enrolled from January 12, 2010 to March 24, 2011. Fifteen patients were enrolled in this trial（8 and 7 for GGGS and oseltamivir, respectively). RT-PCR was positive for pandemic influenza A（H1N1）in 10 patients. The patients were provided with either GGGS or ／ oseltamivir for 5 days. The primary outcome was mortality and／or hospitalization 7 days after the initial diagnosis.
Body temperature and other clinical characteristics were also evaluated.
Results: All patients recovered from illness without complication or hospitalization. The mean time to resolve symptoms for the GGGS and oseltamivir groups was 3.9 days and 3.3 days, respectively（p＝0.43). The GGGS group appeared to have a smaller symptom score AUC than the oseltamivir group,（p＝0.26). Time to recover activity level appeared to be shorter in the GGGS group （p＝0.10), with shorter time to recover health status （p＝0.02). Subgroup analysis on patients with positive PCR showed similar results between the two groups.
Conclusion: GGGS was associated with symptom improvements resembling oseltamivir for both influenza and ILI.
Randomized controlled trials involving larger sample sizes are needed to confirm these results.
become increasingly anxious about this disease, and this has led clinicians to use neuraminidase inhibitors routinely in Japan. This tendency made it very difficult for us to conduct a randomized doubleblinded study, thus we designed a less desirable yet more acceptable open-label trial without randomization.
Settings
The study was conducted at a walk-in outpatient clinic at Kobe University Hospital, Kobe, Japan, and 4 private outpatient clinics in the Kansai area, Honshu （Main island), Japan. The study was originally intended to enroll approximately 100 patients; however, it was decided to terminate the study in March 2011 due to an unexpectedly low number of subjects enrolled and a lack of funding. RNA was extracted and isolated from samples by using the QIAamp Viral RNA Mini Kit（Qiagen K. K.-Japan, Tokyo, Japan). The RNA was then subjected to one step RT-PCR using Super Scripts Ⅲ One-step
RT-PCR System with Platinum® Taq DNA Polymerase（Invitrogen, U. S. A.).
Outcomes
Since there was a genuine concern for increased mortality without the use of neuraminidase inhibitors in Japan during the study period, relatively conservative primary outcomes were selected. Consequently, the primary outcomes selected became mortality ／ and／or hospitalization at day-7 after the initial diagnosis.
Secondary outcomes were total symptom score AUC（area under the curve), total subjective activity level AUC, total subjective health status AUC, time to alleviation of illness, time to recovery of subjective activity level and health status. The time to alleviation of illness was defined as the time from the beginning of the study treatment to the time that 7 key symptoms typical of natural influenza had reduced to absent or mild. 6, 7 Time to recovery of subjective activity level and health status was defined as score achievements of 8 or above.
Statistics
All statistical tests were 2-sided, and we considered a p value＜0.05 to be statistically significant. Student s t-test was used for comparisons of two group characteristics. Wilcoxon rank-sum test was used to compare differences in AUC values. The time to alleviation of symptoms, the time to recovery of activity level and health status was compared using a logrank test. Analyses were performed using STATA version 11 for Macintosh（StataCorp, College Station, TX).
RESULTS
In total 15 patients were enrolled in this trial.
Median age was 28（range 17-39). Patient characteristics are provided in Table 1 . As per inclusion criteria, no patient had any underlying medical condition. One patient had a history of an elbow fracture and another had received LASIK（Laser-assisted in situ keratomileusis）eye surgery for myopia. We did not consider these as underlying medical conditions. Only one patient was vaccinated for influenza in the previous autumn. This patient developed influenza A during the study period and was administered GGGS. One patient in the GGGS arm disclosed that he took one tablet of over the counter NSAIDs during the study period. Meanwhile, another patient in the oseltamivir arm disclosed that he received 500 ml of intravenous normal saline hydration on day 3, when he returned to his primary physician with headache. We judged these patients who received these treatments eligible for inclusion in the analysis. Every patient completed the trial.
RT-PCR was positive for pandemic influenza A （H1N1）in 10 patients. No other influenza virus was detected（Table 1).
By day-7, every patient had recovered from illness.
One patient discontinued GGGS due to somnolence during daytime and the bitter taste of the medication.
Only one patient in the oseltamivir group reported adverse event（headache as aforementioned).
The mean times to resolve symptoms for the GGGS group and oseltamivir were 3.9 days（95% CI 2.83- However, overuse of neuraminidase inhibitors may pose a number of problems. For example, oseltamivir resistance became common in seasonal influenza A （H1N1). Oseltamivir resistance is also found in other types of influenza. 15, 16 Peramivir is considered to have the same mechanism of developing resistance with oseltamivir（H275Y mutation). 17 Zanamivir resistance is rare but documented to occur. Few studies exist on GGGS but there exist a number of studies on GGS. GGS has an antipyretic quality and exerts antiviral effects. 23, 24 In addition, GGS has the efficacy of clearing away heat, relieving pain, counteracting hypersusceptibility, and counteracting bacterial and viral infections. 25 GGS has shown therapeutic effects on bacterial and viral infections in mice. 26 The antipyretic action of GGS regulates elevated serum IL-1 levels produced in influenzainfected mice. 23 In addition, two components contained in GGS were shown to have antiviral qualities in mice infected with influenza virus. 24, 27 In a murine model, GGS showed immunomodulatory effects against lipopolysaccharide induced lung inflammation. The present study is a pilot study to investigate the efficacy of GGGS against influenza and ILI. For both confirmed influenza and ILI, the results of GGGS were comparable to oseltamivir, and there were no cases of hospitalization or mortality（our primary outcomes).
Time to recovery appeared shorter in patients administered GGGS in comparison to patients provided with oseltamivir. There were no significant adverse effects observed in the present study.
Oseltamivir is not expected to be effective against ILI, but in actual practice, it is often used due to the lack of rapid and accurate tests for influenza. Therefore, including patients with ILI in this study was considered relevant and logical from a clinical perspective.
There is some expert opinion that the mortality due to the pandemic influenza in 2009 was very low in Japan because most patients received neuraminidase inhibitors. 31 However, the recent Cochrane reviews did not demonstrate evidence of neuraminidase inhibitors preventing complications or hospitalization. 32, 33 In order to maintain stockpiles of medications on reserve for genuine pandemics, to prevent the emergence of drug resistance, and to avoid unnecessary side effects, the universal application of neuraminidase inhibitors to uncomplicated between two groups（data not shown), there appeared more male in GGGS group（87.5% vs 57.1%).
Since citizens are calmer as of this writing, larger clinical trials with randomization may be possible.
Finally, we did not examine the oseltamivir resistance in confirmed influenza, but the incidence in Japan during that period was quite low（0.5%), 34 which makes the risk almost negligible.
CONCLUSION
Although we were not able to evaluate our primary outcome such as mortality due to the small sample size, our results suggest that GGGS may be as effective as oseltamivir in the management of uncomplicated influenza and ILI in adults. GGGS may be a potential alternative to mainstream pharmaceuticals that could be beneficial if adopted in clinical practice. Further studies are needed to confirm our findings.
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